As of 2024-12-14, the EV/EBITDA ratio of Seres Therapeutics Inc (MCRB) is -0.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MCRB's latest enterprise value is 83.19 mil USD. MCRB's TTM EBITDA according to its financial statements is -154.02 mil USD. Dividing these 2 quantities gives us the above MCRB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 16.8x | 15.9x |
| Forward P/E multiples | 15.2x - 21.1x | 15.5x |
| Fair Price | (13.32) - (14.76) | (13.77) |
| Upside | -1616.0% - -1780.3% | -1667.4% |
| Date | EV/EBITDA |
| 2024-11-29 | -0.65 |
| 2024-11-27 | -0.58 |
| 2024-11-26 | -0.54 |
| 2024-11-25 | -0.55 |
| 2024-11-22 | -0.42 |
| 2024-11-21 | -0.38 |
| 2024-11-20 | -0.47 |
| 2024-11-19 | -0.33 |
| 2024-11-18 | -0.21 |
| 2024-11-15 | -0.18 |
| 2024-11-14 | -0.22 |
| 2024-11-13 | -0.22 |
| 2024-11-12 | -0.30 |
| 2024-11-11 | -0.33 |
| 2024-11-08 | -0.36 |
| 2024-11-07 | -0.36 |
| 2024-11-06 | -0.40 |
| 2024-11-05 | -0.47 |
| 2024-11-04 | -0.46 |
| 2024-11-01 | -0.48 |
| 2024-10-31 | -0.47 |
| 2024-10-30 | -0.43 |
| 2024-10-29 | -0.42 |
| 2024-10-28 | -0.34 |
| 2024-10-25 | -0.35 |
| 2024-10-24 | -0.35 |
| 2024-10-23 | -0.41 |
| 2024-10-22 | -0.43 |
| 2024-10-21 | -0.47 |
| 2024-10-18 | -0.51 |
| 2024-10-17 | -0.50 |
| 2024-10-16 | -0.50 |
| 2024-10-15 | -0.47 |
| 2024-10-14 | -0.49 |
| 2024-10-11 | -0.46 |
| 2024-10-10 | -0.42 |
| 2024-10-09 | -0.39 |
| 2024-10-08 | -0.42 |
| 2024-10-07 | -0.48 |
| 2024-10-04 | -0.51 |
| 2024-10-03 | -0.49 |
| 2024-10-02 | -0.57 |
| 2024-10-01 | -0.63 |
| 2024-09-30 | -0.61 |
| 2024-09-27 | -0.58 |
| 2024-09-26 | -0.49 |
| 2024-09-25 | -0.58 |
| 2024-09-24 | -0.80 |
| 2024-09-23 | -0.85 |
| 2024-09-20 | -0.82 |